Adrenocortical carcinoma.
ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival. Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.
Rodgers
Steven E
SE
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA.
Evans
Douglas B
DB
Lee
Jeffrey E
JE
Perrier
Nancy D
ND
D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D018268:Adrenocortical Carcinoma / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D001506:Beckwith-Wiedemann Syndrome / Q000235:genetics; D001707:Biopsy, Needle; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007335:Insulin-Like Growth Factor II; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D011506:Proteins / Q000235:genetics
C035170:IGF2 protein, human; D011506:Proteins; D007335:Insulin-Like Growth Factor II; D006854:Hydrocortisone